{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:30:54Z","timestamp":1793442654142,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030728","name":"Debiopharm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy OPEN"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.hpopen.2026.100177","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:20:12Z","timestamp":1784330412000},"page":"100177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics"],"prefix":"10.1016","volume":"11","author":[{"given":"Jennifer","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Amersdorffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meindert","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Duffy-Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Ivezic-Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Vanbiervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpopen.2026.100177_bb0005","author":"WHO"},{"key":"10.1016\/j.hpopen.2026.100177_bb0010","series-title":"Countries enabled to address antimicrobial resistance through strengthened surveillance systems, laboratory capacity, infection prevention and control, awareness-raising and evidence-based policies and practices","author":"WHO","year":"2026"},{"issue":"10459","key":"10.1016\/j.hpopen.2026.100177_bb0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hpopen.2026.100177_bb0020","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2468-2667(22)00225-0","article-title":"The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis","volume":"7","author":"Mestrovic","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.hpopen.2026.100177_bb0025","author":"Anderson"},{"key":"10.1016\/j.hpopen.2026.100177_bb0030","author":"MOULAC"},{"key":"10.1016\/j.hpopen.2026.100177_bb0035","author":"WHO"},{"key":"10.1016\/j.hpopen.2026.100177_bb0040","article-title":"Challenges and opportunities for incentivising antibiotic research and development in Europe","volume":"33","author":"Anderson","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100177_bb0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1057\/s41599-024-03374-x","article-title":"Changes in revenues associated with antimicrobial reimbursement reforms in Germany","volume":"11","author":"McEnany","year":"2024","journal-title":"Humanities and social sciences Communications"},{"key":"10.1016\/j.hpopen.2026.100177_bb0050","article-title":"Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs","volume":"1","author":"Suda","year":"2022","journal-title":"BMJ Medicine"},{"issue":"7","key":"10.1016\/j.hpopen.2026.100177_bb0055","doi-asserted-by":"crossref","first-page":"e1696","DOI":"10.1093\/cid\/ciaa1353","article-title":"Methodological and reporting quality of noninferiority randomized controlled trials comparing antibiotic therapies: a systematic review","volume":"73","author":"Bai","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.hpopen.2026.100177_bb0060","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1016\/S1473-3099(19)30284-1","article-title":"Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials","volume":"19","author":"Lanini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.hpopen.2026.100177_bb0065","article-title":"How should the value attributes of novel antibiotics be considered in reimbursement decision making?","author":"Morton","year":"2019","journal-title":"Medical Decision Making Policy & Practice"},{"key":"10.1016\/j.hpopen.2026.100177_bb0070","article-title":"Antimicrobial resistance: is health technology assessment part of the solution or part of the problem?","author":"Drummond","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.hpopen.2026.100177_bb0075","article-title":"Assessing the value of new antimicrobials: evaluations of Cefiderocol and Ceftazidime-avibactam to inform delinked payments by the NHS in England","author":"Woods","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"10.1016\/j.hpopen.2026.100177_bb0080","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/cid\/ciaa153","article-title":"Financing pull mechanisms for antibiotic-related innovation: opportunities for Europe","volume":"71","author":"\u00c5rdal","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.hpopen.2026.100177_bb0085","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.3390\/healthcare10122546","article-title":"Last resort antibiotics costs and reimbursement analysis of real-life ICU patients with pneumonia caused by multidrug-resistant gram-negative bacteria in Germany","volume":"10","author":"Jeck","year":"2022","journal-title":"Healthcare"},{"issue":"8","key":"10.1016\/j.hpopen.2026.100177_bb0090","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","article-title":"Do patient access schemes for high-cost cancer drugs deliver value to society? Lessons from the NHS cancer drugs fund","volume":"28","author":"Aggarwal","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hpopen.2026.100177_bb0095","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0093","article-title":"Flexibility in assessment of rare disease technologies via NICE\u2019s single technology appraisal route: a thematic analysis","volume":"12","author":"Hale","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"14","key":"10.1016\/j.hpopen.2026.100177_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/IDR.S287792","article-title":"Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study","volume":"5","author":"Dutescu","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.hpopen.2026.100177_bb0110","author":"England"},{"key":"10.1016\/j.hpopen.2026.100177_bb0115","author":"Agency"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100177_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014605","article-title":"Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation","volume":"9","author":"Berner-Rodoreda","year":"2024","journal-title":"BMJ Glob Health"},{"issue":"11","key":"10.1016\/j.hpopen.2026.100177_bb0130","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1377\/hlthaff.2021.00688","article-title":"Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines","volume":"40","author":"Outterson","year":"2021","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100177_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-020-01462-0","article-title":"Are supplemental appraisal\/reimbursement processes needed for rare disease treatments? An international comparison of country approaches","volume":"15","author":"Nicod","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.hpopen.2026.100177_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.902150","article-title":"How can we optimize the value assessment and appraisal of orphan drugs for reimbursement purposes? A qualitative interview study across European countries","volume":"13","author":"Blonda","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hpopen.2026.100177_bb0160","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0290","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0295","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0300","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0305","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0310","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0315","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0185","author":"Bundesausschuss"},{"key":"10.1016\/j.hpopen.2026.100177_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2023.104892","article-title":"Value assessment of antimicrobials using the STEDI framework - how steady is the outcome?","volume":"136","author":"Brassel","year":"2023","journal-title":"Health Policy"},{"key":"10.1016\/j.hpopen.2026.100177_bb0195","series-title":"FRAMEWORK FOR VALUE ASSESSMENT OF NEW ANTIMICROBIALS: Implications of alternative funding arrangements for NICE Appraisal","author":"WB","year":"2024"},{"key":"10.1016\/j.hpopen.2026.100177_bb0200","article-title":"Guidance for demonstrating the societal value of new antibiotics. Review","volume":"11 - 2020","author":"Simoens","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100177_bb0205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12879-025-10481-w","article-title":"Antimicrobial resistance of bacterial pathogens isolated from cancer patients: a systematic review and meta-analysis","volume":"25","author":"Ntim","year":"2025","journal-title":"BMC Infect Dis"}],"container-title":["Health Policy OPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:41:20Z","timestamp":1793439680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590229626000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S2590229626000171"],"URL":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100177","relation":{},"ISSN":["2590-2296"],"issn-type":[{"value":"2590-2296","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics","name":"articletitle","label":"Article Title"},{"value":"Health Policy OPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100177"}}